REMPARXX
Dead / Abandoned — Abandoned — no statement of use filed (as of 05 Jun 2023)
What this means for you
This application is over — abandoned 05 Jun 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88671889
- Mark type
- Stylized text
- Filed
- 29 Oct 2019
- Published for opposition
- 10 Mar 2020
- Abandoned
- 05 Jun 2023
- Attorney of record
- Mark A. Paskar
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical injectable drugs for the treatment and prevention of Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis
Owner
- Sagent Pharmaceuticals, Inc., Schaumburg, IL, US
- Sagent Pharmaceuticals, Inc., Schaumburg, IL, US
Prosecution history
- 05 Jun 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 05 Jun 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 16 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Nov 2022 — SOU EXTENSION 5 GRANTED
- 04 Nov 2022 — SOU EXTENSION 5 FILED
- 15 Nov 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Nov 2022 — SOU TEAS EXTENSION RECEIVED
- 02 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Mar 2022 — SOU EXTENSION 4 GRANTED
- 31 Mar 2022 — SOU EXTENSION 4 FILED
- 31 Mar 2022 — SOU TEAS EXTENSION RECEIVED
- 23 Oct 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Oct 2021 — SOU EXTENSION 3 GRANTED
- 21 Oct 2021 — SOU EXTENSION 3 FILED
- 21 Oct 2021 — SOU TEAS EXTENSION RECEIVED